BeiGene to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference

CAMBRIDGE, Mass. & BEIJING & BASEL, Switzerland--(BUSINESS WIRE)-- BeiGene Co.,Ltd (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that Julia Wang, Chief Financial Officer, and Angus Grant, Ph.D., Chief Business Executive, will participate in a fireside chat at the Goldman Sachs 43^rd Annual Global Healthcare Conference on Tuesday, June 14, 2022, at 8:40 a.m. PT.

A live webcast can be accessed from the investors section of BeiGene’s website at http://ir.beigene.com, http://hkexir.beigene.com or https://sseir.beigene.com. An archived replay will be available for 90 days following the event.

About BeiGene

BeiGene is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide. With a broad portfolio of more than 40 clinical candidates, we are expediting development of our diverse pipeline of novel therapeutics through our own capabilities and collaborations. We are committed to radically improving access to medicines for two billion more people by 2030. BeiGene has a growing global team of over 8,000 colleagues across five continents. To learn more about BeiGene, please visit www.beigene.com and follow us on Twitter at @BeiGeneGlobal.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220607006383/en/